Results 141 to 150 of about 149,963 (343)

Clinical Outcome Assessments in Parkinson's Disease: A Scoping Review of Current Rating Scales and Future Needs

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Clinical outcome assessments (COAs) are essential for evaluating symptom severity, treatment response, and disease progression in Parkinson's disease (PD). As clinical knowledge evolves, it is necessary to revisit the recommendation status on the COAs to ensure their continued relevance and validity. Objectives To provide an updated
Evita Papathoma   +14 more
wiley   +1 more source

Clinical and Radiological Evolution of Idiopathic Normal Pressure Hydrocephalus: A Critical Review

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background The pathophysiology of idiopathic normal pressure hydrocephalus (iNPH) remains poorly understood. While it is commonly accepted that iNPH has an insidious onset, little is known about its preclinical and early stages and its development over time.
David Campo‐Caballero   +6 more
wiley   +1 more source

Loss‐of‐Function Variants in CPT1C: No Support for a Causal Role in Hereditary Spastic Paraplegia

open access: yesMovement Disorders, EarlyView.
Abstract Background Hereditary spastic paraplegias (HSPs) are neurodegenerative disorders characterized by lower‐limb spasticity. Pathogenic variants in CPT1C have been implicated in HSP. Objective The objective of this study was to assess whether CPT1C loss‐of‐function (LOF) variants are causally associated with HSP.
Rui Zhu   +17 more
wiley   +1 more source

Is surgery effective for reducing symptoms in adults with obstructive sleep apnea? [PDF]

open access: yes, 2001
Current evidence is insufficient to recommend surgery for symptom relief for patients with obstructive sleep apnea. More convincing evidence exists supporting the use of Continuous Positive Airway Pressure (CPAP) or dental appliances for reducing ...
Smith, Peter C.
core  

Weekly Subcutaneous VK2735, a GIP/GLP‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study

open access: yesObesity, EarlyView.
Four doses of VK2735 and a placebo group were included in the VENTURE study. Adults who were overweight or had obesity had significant weight loss when taking any dose of VK2735 for 13 weeks. More people lost at least 10% of their body weight as the dose increased.
Harold E. Bays   +9 more
wiley   +1 more source

Prevalence, Severity, and Prognostic Value of Sleep Apnea Syndromes in Cardiac Amyloidosis. [PDF]

open access: yesSleep, 2016
Bodez D   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy